Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Loures

67 clinical trials in Loures, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Loures at a glance
67
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

67 trials in Loures

Open in trial search

Focal segmental glomerulosclerosis

Recruiting
InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Colitis ulcerative

Recruiting
InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:XMAB942
  • Sponsor:Xencor Inc.

Cardiovascular disorder+1

Recruiting
InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.

Chronic obstructive pulmonary disease

Recruiting
Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Breast cancer

Recruiting
Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Major depression

Recruiting
InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:SELTOREXANT
  • Sponsor:Janssen Cilag International

Chronic rhinosinusitis with nasal polyps

Recruiting
Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Recruiting
InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Non-small cell lung cancer

Recruiting
Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Colorectal cancer

Recruiting
Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting
Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

HER2 positive breast cancer

Recruiting
Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Loures

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, particularly exploring new therapies for HER2-positive and hormone receptor-positive variants. Studies include novel combinations of targeted therapies and immunotherapy approaches.

  • Advanced breast cancer therapies
  • HER2-positive treatment strategies
  • Non-small cell lung cancer interventions

Research includes evaluation of drugs like trastuzumab deruxtecan and combination therapies targeting specific cancer mutations.

02 Neurological Disorders

Comprehensive studies investigating treatments for multiple sclerosis and neurodegenerative conditions. Research focuses on both relapsing and progressive forms of MS, along with early-stage Alzheimer's disease.

  • Multiple sclerosis therapies
  • Alzheimer's disease treatments
  • Cognitive function studies

Trials evaluate medications like ocrelizumab and semaglutide for various neurological conditions.

03 Inflammatory Conditions

Advanced research into inflammatory bowel diseases, including studies on Crohn's Disease and Ulcerative Colitis. Trials evaluate novel therapeutic approaches and combination treatments.

  • Crohn's Disease management
  • Ulcerative Colitis treatments
  • Combination therapy approaches

Studies investigate medications such as risankizumab and ozanimod for long-term disease management.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).